Enhanced Releases Aggregate Substance Usage Data Ahead of Competition With Study Now Available for Review on Clinicaltrials.org 91% of Athletes in Trial Used Testosterone as Part of Individualized Protocols NEW YORK, May 20, 2026 /PRNewswire/ -- Enhanced (NYSE: ENHA), the elite sports competition and consumer products company, today announced that its Institutional Review Board (IRB) approved clinical study has been posted for review to ClinicalTrials.gov. The study is part of the Enhanced Medical Program, which gives athletes the opportunity to consider FDA-approved substances, prescribed by doctors as part of the study, and continuous medical screenings to explore enhancements in the safest possible manner.